Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) has earned an average rating of "Buy" fro...
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Free Report) – Analysts at Leerink Partnrs raised their FY...
Guggenheim reiterated their buy rating on shares of Larimar Therapeutics (NASDAQ:LRMR – Free Report)...
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Free Report) – Investment analysts at Lifesci Capital issu...